FARMINGTON, Conn., March 20, 2013 /PRNewswire-iReach/ — The dynamic global pharmaceutical market represents trillions of dollars in economic activity. Partnerships, licensing agreements, investments and merger and acquisition deals account for a significant part of this active industry. Pharmaceutical deal headliners for February include: Biogen Idec acquisition of Elan’s interest in Multiple Sclerosis drug Tysabri for $3.2 billion, Cardinal Health acquisition of AssuraMed for up to $2.07 billion, Mylan acquisition of Agila and Specialties from Strides Arcolab for up to $1.85 billion. Other major activity in the pharma sphere include Quintiles Transnational filing for IPO to raise up to $600 million and Chiasma’s licensing agreement with Roche for Octreolin.

To help companies and investors prepare for negotiations and enhance decision making capabilities by staying up-to-date and understanding deal structures in the pharmaceutical industry, “Partnerships, Licensing, Investments and M&A Deals and Trends for February 2013 in Pharmaceuticals“, a new report by GlobalData, provides an analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals.

Deal trends are reviewed for the following segments: cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women’s health.

Learn more and request free sample pages at http://www.giiresearch.com/report/gd248823-partnerships-licensing-investments-m-deals-trends.html

Global Information (GII) also distributes dozens of reports annually providing detailed analyses of deal terms. These reports, published by GII’s partner publisher Current Partnering, a division of Wildwood Ventures, seek to cover all aspects of partnering best practice and deal terms, providing users with the information and insight required to optimize their partnering activities. Below is just a selection:

“Oral Health Partnering 2007-2013” provides understanding and access to the oral health partnering deals and agreements entered into by the world’s leading healthcare companies. This data driven report contains over 20 links to online copies of actual oral health deals and contract documents.

Learn more and request free sample pages at http://www.giiresearch.com/report/wild263466-oral-health-partnering.html

“Infectives Vaccine Partnering Terms and Agreements” provides details of the latest infectives vaccine agreements announced in the healthcare sectors. This report contains a comprehensive listing of all infectives vaccine partnering deals announced since January 2007, including financial terms where available, including over 300 links to online deal records of actual vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Learn more and request free sample pages at http://www.giiresearch.com/report/wild253250-dermatology-partnering-terms-agreements.html

“Dermatology Partnering Terms and Agreements” provides a detailed understanding and analysis of how and why companies enter dermatology partnering deals. The majority of deals are discovery, preclinical or development stage whereby the licensee obtains a right or an option right to license the licensors dermatology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Learn more and request free sample pages at http://www.giiresearch.com/report/wild253250-dermatology-partnering-terms-agreements.html

Find more market research for the pharmaceutical industry

With nearly 30 years of market research experience, Global Information, Inc (GII) is the single best resource for companies entering new markets, expanding their business, and securing their positions in their respective industries. With tens of thousands of reports from over 400 publishers in nearly every vertical market, our market research and forecast data can give companies the edge they need to stay ahead of the competition and plan for every contingency.

The reports above are just a few examples from the hundreds of research reports we have available for the pharmaceutical market. For a free consultation on the market research you need, contact us today!

About Global Information Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.

Media Contact: Jeremy Palaia Global Information, Inc., 1-860-674-8796, Press@gii.co.jp

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Global Information, Inc.